Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Summary
The study is being conducted to evaluate the efficacy and safety of HRS9531 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors compared to Semaglutide QW for 36 weeks and 52 weeks.
Official title: A Phase III,Multicenter,Randomized,Open-label,Parallel-controlled Study Comparing the Efficacy and Safety of HRS9531 With Semaglutide in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Metformin Monotherapy or in Combination With SGLT2 Inhibitors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
884
Start Date
2024-10-31
Completion Date
2026-09-30
Last Updated
2025-06-12
Healthy Volunteers
No
Conditions
Interventions
HRS9531 Injection
HRS9531 injected subcutaneously once weekly.
Semaglutide Injection
Semaglutide injected subcutaneously once weekly.
Locations (1)
Zhu Xianyi Memorial Hospital,Tianjin Medical University
Tianjin, Tianjin Municipality, China